LU92517I2 - Delamanide et ses dérivés pharmaceutiquement acceptables - Google Patents

Delamanide et ses dérivés pharmaceutiquement acceptables

Info

Publication number: LU92517I2
Authority: LU; Luxembourg
Prior art keywords: delamanide; pharmaceutically acceptable; acceptable derivatives; derivatives; pharmaceutically
Prior art date: 2002-10-11

Application number

LU92517C

Other languages

English (en)

Original Assignee

Otsuka Pharma Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-10-11

Filing date

2014-08-13

Publication date

2014-10-13

2014-08-13 Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd

2014-10-13 Publication of LU92517I2 publication Critical patent/LU92517I2/fr

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/20—Spiro-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Pulmonology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

LU92517C 2002-10-11 2014-08-13 Delamanide et ses dérivés pharmaceutiquement acceptables LU92517I2 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP2002298259		2002-10-11

Publications (1)

Publication Number	Publication Date
LU92517I2 true LU92517I2 (fr)	2014-10-13

Family

ID=32089299

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LU92517C LU92517I2 (fr)	2002-10-11	2014-08-13	Delamanide et ses dérivés pharmaceutiquement acceptables

Country Status (27)

Country	Link
US (1)	US7262212B2 (fr)
EP (2)	EP1555267B1 (fr)
JP (1)	JP4186065B2 (fr)
KR (1)	KR100723847B1 (fr)
CN (4)	CN101255170A (fr)
AR (4)	AR041198A1 (fr)
AU (1)	AU2003272979B2 (fr)
BE (1)	BE2014C053I2 (fr)
BR (1)	BRPI0314344B8 (fr)
CA (1)	CA2497569C (fr)
CY (2)	CY1113578T1 (fr)
DK (1)	DK1555267T3 (fr)
ES (1)	ES2400179T3 (fr)
FR (1)	FR14C0066I2 (fr)
HK (2)	HK1085463A1 (fr)
HU (1)	HUS1400046I1 (fr)
LU (1)	LU92517I2 (fr)
MX (1)	MXPA05003674A (fr)
MY (1)	MY139244A (fr)
PL (3)	PL404913A1 (fr)
PT (1)	PT1555267E (fr)
RU (1)	RU2326121C3 (fr)
SI (1)	SI1555267T1 (fr)
TW (1)	TWI347946B (fr)
UA (1)	UA83200C2 (fr)
WO (1)	WO2004033463A1 (fr)
ZA (1)	ZA200501033B (fr)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE60144284D1 (de)	2000-11-01	2011-05-05	Millennium Pharm Inc	Stickstoffhaltige heterozyklische verbindungen und verfahren zu deren herstellung
ES2526892T3 (es) *	2002-10-15	2015-01-16	Otsuka Pharmaceutical Co., Ltd.	Método para preparar un compuesto 2-halo-4-nitroimidazol
BRPI0414909A (pt)	2003-10-31	2006-11-07	Otsuka Pharma Co Ltd	composto, agente antituberculoso, e, método para produzir um composto
JP4761756B2 (ja) *	2003-10-31	2011-08-31	大塚製薬株式会社	２，３−ジヒドロイミダゾ［２，１−ｂ］オキサゾ−ル化合物
TWI300409B (en)	2004-02-18	2008-09-01	Otsuka Pharma Co Ltd	Method for producing 4-nitroimidazole compound
DK1731518T3 (da)	2004-03-31	2014-09-29	Nippon Soda Co	Cyklisk aminsammensætning og skadedyrsbekæmpelsesmiddel
JP4789966B2 (ja) *	2004-04-09	2011-10-12	大塚製薬株式会社	医薬組成物
JP4787529B2 (ja) *	2004-04-09	2011-10-05	大塚製薬株式会社	医薬組成物
CA2609957A1 (fr) *	2005-06-20	2007-01-04	Schering Corporation	Piperidines substituees liees a un atome de carbone et leurs derives utiles en tant qu'antagonistes de l'histamine h3
CA2610749C (fr) *	2005-07-28	2013-06-04	Otsuka Pharmaceutical Co., Ltd.	Composition pharmaceutique comprenant des derives de 2,3-dihydro-6-nitroimidazo [2,1-b] oxazole
TW201434467A (zh) *	2005-10-05	2014-09-16	Otsuka Pharma Co Ltd	抗結核治療藥物及含彼之套組
JP5105818B2 (ja) *	2005-10-05	2012-12-26	大塚製薬株式会社	医薬組成物
KR101006363B1 (ko)	2005-10-06	2011-01-10	닛뽕소다 가부시키가이샤	가교 고리형 아민 화합물 및 유해 생물 방제제
TW200800268A (en) *	2005-11-04	2008-01-01	Otsuka Pharma Co Ltd	Medicinal composition showing improved drug absorbability
US7750012B2 (en)	2005-12-21	2010-07-06	Decode Genetics Ehf	Biaryl nitrogen-heterocycle inhibitors of LTA4H for treating inflammation
CA2640304A1 (fr) *	2006-02-13	2007-08-23	Laboratoires Serono S.A.	Derives de sulfonamide dans le traitement d'infections bacteriennes
JP2007297305A (ja) *	2006-04-28	2007-11-15	Daiso Co Ltd	Ｎ−（２，３−エポキシ−２−メチルプロピル）フタルイミドの製造法
WO2008106128A2 (fr) *	2007-02-26	2008-09-04	Vitae Pharmaceuticals, Inc.	Inhibiteurs d'urée et de carbamate de 11b-hydroxystéroïde déshydrogénase 1 cycliques
AR070301A1 (es) *	2007-05-08	2010-03-31	Otsuka Pharma Co Ltd	Compuesto epoxi y metodo para producir el mismo
AR067673A1 (es) *	2007-07-26	2009-10-21	Vitae Pharmaceuticals Inc	Derivados de 1,3 oxazinan - 2 - ona como inhibidores ciclicos de la 11 beta -hidroxiesteroide deshidrogenasa 1. composiciones farmaceuticas.
WO2009021965A2 (fr) *	2007-08-15	2009-02-19	Glaxo Group Limited	Composés
WO2009050204A1 (fr) *	2007-10-16	2009-04-23	Glaxo Group Limited	Dérivés de quinoléine utilisés pour traiter des maladies inflammatoires et allergiques
AR069207A1 (es) *	2007-11-07	2010-01-06	Vitae Pharmaceuticals Inc	Ureas ciclicas como inhibidores de la 11 beta - hidroxi-esteroide deshidrogenasa 1
CA2708303A1 (fr)	2007-12-11	2009-06-18	Vitae Pharmaceuticals, Inc.	Inhibiteurs cycliques d'uree de la 11.beta.-hydroxysteroide dehydrogenase 1
TW200934490A (en) *	2008-01-07	2009-08-16	Vitae Pharmaceuticals Inc	Lactam inhibitors of 11 &abgr;-hydroxysteroid dehydrogenase 1
JP5490020B2 (ja)	2008-01-24	2014-05-14	ヴァイティーファーマシューティカルズ，インコーポレイテッド	１１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状カルバゼート及びセミカルバジドインヒビター
JP5734666B2 (ja) *	2008-02-11	2015-06-17	ヴァイティーファーマシューティカルズ，インコーポレイテッド	１１β−ヒドロキシステロイドデヒドロゲナーゼ１の１，３−オキサアゼパン−２−オン及び１，３−ジアゼパン−２−オン阻害剤
CA2715290A1 (fr) *	2008-02-15	2009-08-20	Vitae Pharmaceuticals, Inc.	Inhibiteurs de la 11 beta-hydroxysteroide dehydrogenase 1
WO2009117109A1 (fr) *	2008-03-18	2009-09-24	Vitae Pharmaceuticals, Inc.	Inhibiteurs de la 11-bêta-hydroxystéroïde déshydrogénase de type 1
JP5613656B2 (ja) *	2008-03-26	2014-10-29	グローバル、アライアンス、フォア、ティービー、ドラッグ、ディベロップメント	置換されたフェニルオキサゾリジノンと共有結合した二環式ニトロイミダゾール
AR071236A1 (es)	2008-05-01	2010-06-02	Vitae Pharmaceuticals Inc	Inhibidores ciclicos de la 11beta-hidroxiesteroide deshidrogenasa 1
NZ588954A (en)	2008-05-01	2012-08-31	Vitae Pharmaceuticals Inc	Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
US8242111B2 (en) *	2008-05-01	2012-08-14	Vitae Pharmaceuticals, Inc.	Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1
CA2723034A1 (fr)	2008-05-01	2009-11-05	Vitae Pharmaceuticals, Inc.	Inhibiteurs cycliques de la 11-beta-hydroxysteroide dehydrogenase 1
CN102119160B (zh)	2008-07-25	2014-11-05	贝林格尔·英格海姆国际有限公司	11β-羟基类固醇脱氢酶1的环状抑制剂
JP5777030B2 (ja)	2008-07-25	2015-09-09	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	１１β−ヒドロキシステロイドデヒドロゲナーゼ１の阻害剤
US9540322B2 (en)	2008-08-18	2017-01-10	Yale University	MIF modulators
PE20110368A1 (es) *	2008-08-18	2011-06-13	Univ Yale	Moduladores de mif
US9643922B2 (en)	2008-08-18	2017-05-09	Yale University	MIF modulators
WO2010143007A1 (fr) *	2009-06-10	2010-12-16	Dynamit Nobel Gmbh Explosivstoff-Und Systemtechnik	Procédé de production de 2-halogéno-4-nitroimidazole
EP2323990B1 (fr) *	2008-08-21	2014-06-18	Dynamit Nobel GmbH Explosivstoff- und Systemtechnik	Procédés pour la fabrication de 2-halo-4-nitroimidazole et leurs intermédiaires
EP2393807B1 (fr)	2009-02-04	2013-08-14	Boehringer Ingelheim International GmbH	Inhibiteurs cycliques de la 11beta -hydroxystéroïde déshydrogénase 1
TW201039034A (en) *	2009-04-27	2010-11-01	Chunghwa Picture Tubes Ltd	Pixel structure and the method of forming the same
GEP20156309B (en) *	2009-04-30	2015-07-10	Vitae Pharmaceuticals Inc	Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
US8680093B2 (en)	2009-04-30	2014-03-25	Vitae Pharmaceuticals, Inc.	Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
JP5656986B2 (ja)	2009-06-11	2015-01-21	ヴァイティーファーマシューティカルズ，インコーポレイテッド	１，３−オキサジナン−２−オン構造に基づく１１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状阻害剤
JP5749263B2 (ja)	2009-07-01	2015-07-15	ヴァイティーファーマシューティカルズ，インコーポレイテッド	１１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状インヒビター
ES2530266T3 (es)	2009-07-31	2015-02-27	Global Alliance For Tb Drug Development	Análogos de nitroimidazooxazina y sus usos
US9198913B2 (en)	2009-07-31	2015-12-01	Global Alliance For Tb Drug Development	Nitroimidazooxazines and their uses in anti-tubercular therapy
IN2012DN01414A (fr) *	2009-07-31	2015-06-05	Global Alliance For Tb Drug Dev
WO2011052522A1 (fr)	2009-10-26	2011-05-05	富士フイルムＲｉファーマ株式会社	Agent diagnostique pour maladies infectieuses
TW201200523A (en)	2010-01-29	2012-01-01	Otsuka Pharma Co Ltd	Synthetic intermediate of oxazole compound and method for producing the same
GB201012209D0 (en) *	2010-05-31	2010-09-08	Ge Healthcare Ltd	In vivo imaging agent
EP2582698B1 (fr)	2010-06-16	2016-09-14	Vitae Pharmaceuticals, Inc.	Hétérocycles à 5, 6 et 7 chaînons substitués, médicaments contenant ces composés et leur utilisation
EP2585444B1 (fr)	2010-06-25	2014-10-22	Boehringer Ingelheim International GmbH	Azaspirohexanones comme inhibiteurs de 11-beta -hsd1 pour le traitement de troubles métaboliques
CA2813671A1 (fr)	2010-11-02	2012-05-10	Boehringer Ingelheim International Gmbh	Combinaisons pharmaceutiques destinees au traitement de troubles du metabolisme
CN103596960B (zh)	2011-04-15	2016-11-16	大塚制药株式会社	6,7-二氢咪唑并[2,1-b][1,3]噁嗪杀菌剂
JP2015006994A (ja) *	2011-10-28	2015-01-15	大正製薬株式会社	ジヒドロイミダゾオキサゾール誘導体
US9572809B2 (en)	2012-07-18	2017-02-21	Spero Trinem, Inc.	Combination therapy to treat Mycobacterium diseases
FR3000064A1 (fr)	2012-12-21	2014-06-27	Univ Lille Ii Droit & Sante	Composes de type spiroisoxazoline ayant une activite potentialisatrice de l'activite d'un antibiotique-composition et produit pharmaceutiques comprenant de tels composes
IN2013DE02954A (fr) *	2013-10-04	2015-04-10	Council Scient Ind Res
CN103524492A (zh) *	2013-10-23	2014-01-22	中国药科大学	侧链含硝基咪唑基团取代的喹诺酮类化合物、其制备及用途
TWI687409B (zh)	2014-08-28	2020-03-11	日商大塚製藥股份有限公司	稠合雜環化合物
EP3209669B1 (fr) *	2014-10-21	2018-11-07	Council of Scientific and Industrial Research	1,2,3-triazol-1-yl-méthyl-2,3-dihydro -2-méthyl-6-nitroimidazo [2,1-b]oxazoles substitués comme agents anti-mycobactériens et procédé de préparation associé
CN105732659B (zh) *	2014-12-12	2019-07-16	上海阳帆医药科技有限公司	硝基咪唑类化合物及其制备方法和在制药中的用途
EP3252059A4 (fr) *	2015-01-29	2018-07-11	Medshine Discovery Inc.	Dérivé de nitroimidazole anti-tuberculose pulmonaire
EA201792154A1 (ru) *	2015-03-27	2018-02-28	Оцука Фармасьютикал Ко., Лтд.	Способ получения 1-(4-гидроксифенил)-4-(4- трифторметоксифенокси)пиперидина или его соли
CN106317072B (zh) *	2015-06-17	2020-03-17	盟科医药技术(上海)有限公司	用于分枝杆菌感染治疗的杂环化合物及其应用
JP6905506B2 (ja)	2016-02-26	2021-07-21	大塚製薬株式会社	ピペリジン誘導体
CN105859628B (zh) *	2016-04-19	2018-08-07	清远职业技术学院	一种抗菌化合物对n咪唑苯甲醛缩邻甲苯胺希夫碱及其制备方法和应用
US20190276475A1 (en) *	2016-07-22	2019-09-12	Medshine Discovery Inc.	Crystal and salt of nitroimidazole, and manufacturing method thereof
SI3668879T1 (sl) *	2017-08-16	2022-04-29	Glaxosmithkline Intellectual Property Development Limited	Nove spojine
SG11202011908YA (en)	2018-06-11	2020-12-30	Otsuka Pharma Co Ltd	Delamanid-containing composition
CN109705022A (zh) *	2018-12-28	2019-05-03	上海彩迩文生化科技有限公司	一种芳香胺中间体的制备方法
CN112300192B (zh) *	2019-08-02	2023-08-11	南京长澳医药科技有限公司	硝基咪唑类化合物及其制备方法和用途
CN110483549B (zh) *	2019-08-30	2021-03-05	沈阳药科大学	一种硝基咪唑吡喃类抗结核药物的制备方法
CN110615800A (zh) *	2019-10-16	2019-12-27	李丽丽	硝基咪唑类化合物及其制备方法和用途
CN112156088B (zh) *	2020-10-30	2021-08-31	健民药业集团股份有限公司	一种化合物在制备结核分枝杆菌抑制剂中的用途
CN113603706A (zh) *	2021-08-04	2021-11-05	深圳市泰力生物医药有限公司	德拉马尼的晶型、含有该晶型的活性药物和药物组合物
CN115368252B (zh) *	2022-09-19	2024-01-12	西北农林科技大学	一种4-胺基酚类衍生物及应用
CN116640106B (zh) *	2023-05-11	2024-03-08	郑州大学	一种苯基哌嗪类化合物及其制备方法、应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5668127A (en)	1995-06-26	1997-09-16	Pathogenesis Corporation	Nitroimidazole antibacterial compounds and methods of use thereof

2003
- 2003-10-09 TW TW092128165A patent/TWI347946B/zh not_active IP Right Cessation
- 2003-10-09 AR ARP030103673A patent/AR041198A1/es active IP Right Grant
- 2003-10-10 PL PL404913A patent/PL404913A1/pl unknown
- 2003-10-10 DK DK03754085.3T patent/DK1555267T3/da active
- 2003-10-10 WO PCT/JP2003/013070 patent/WO2004033463A1/fr active Application Filing
- 2003-10-10 AU AU2003272979A patent/AU2003272979B2/en not_active Expired
- 2003-10-10 BR BRPI0314344A patent/BRPI0314344B8/pt active IP Right Grant
- 2003-10-10 SI SI200332254T patent/SI1555267T1/sl unknown
- 2003-10-10 CN CNA2007100040371A patent/CN101255170A/zh active Pending
- 2003-10-10 CN CNB2003801017508A patent/CN100366624C/zh not_active Expired - Lifetime
- 2003-10-10 UA UAA200504391A patent/UA83200C2/ru unknown
- 2003-10-10 PT PT37540853T patent/PT1555267E/pt unknown
- 2003-10-10 ES ES03754085T patent/ES2400179T3/es not_active Expired - Lifetime
- 2003-10-10 CN CNA2007100040367A patent/CN101172981A/zh active Pending
- 2003-10-10 PL PL409525A patent/PL409525A1/pl unknown
- 2003-10-10 US US10/530,429 patent/US7262212B2/en not_active Expired - Lifetime
- 2003-10-10 CN CN201110416170.4A patent/CN102532162B/zh not_active Expired - Lifetime
- 2003-10-10 MX MXPA05003674A patent/MXPA05003674A/es active IP Right Grant
- 2003-10-10 MY MYPI20033866A patent/MY139244A/en unknown
- 2003-10-10 EP EP03754085A patent/EP1555267B1/fr not_active Expired - Lifetime
- 2003-10-10 EP EP12193820.3A patent/EP2570418A3/fr not_active Withdrawn
- 2003-10-10 KR KR1020057004567A patent/KR100723847B1/ko active Protection Beyond IP Right Term
- 2003-10-10 RU RU2005114017A patent/RU2326121C3/ru active Protection Beyond IP Right Term
- 2003-10-10 PL PL376157A patent/PL217919B1/pl unknown
- 2003-10-10 CA CA2497569A patent/CA2497569C/fr not_active Expired - Lifetime
- 2003-10-14 JP JP2003353868A patent/JP4186065B2/ja not_active Expired - Lifetime
2005
- 2005-02-03 ZA ZA200501033A patent/ZA200501033B/en unknown
2006
- 2006-02-03 HK HK06101486A patent/HK1085463A1/xx not_active IP Right Cessation
2012
- 2012-04-23 AR ARP120101394A patent/AR086485A2/es unknown
- 2012-11-21 HK HK12111863.7A patent/HK1171018A1/xx not_active IP Right Cessation
2013
- 2013-01-25 CY CY20131100076T patent/CY1113578T1/el unknown
- 2013-02-08 AR ARP130100408A patent/AR089950A2/es unknown
- 2013-07-15 AR ARP130102514 patent/AR091771A2/es not_active Application Discontinuation
2014
- 2014-08-13 LU LU92517C patent/LU92517I2/fr unknown
- 2014-08-14 HU HUS1400046C patent/HUS1400046I1/hu unknown
- 2014-09-09 BE BE2014C053C patent/BE2014C053I2/fr unknown
- 2014-09-11 FR FR14C0066C patent/FR14C0066I2/fr active Active
- 2014-09-24 CY CY2014041C patent/CY2014041I1/el unknown

Also Published As

Publication number	Publication date
UA83200C2 (en)	2008-06-25
CN101255170A (zh)	2008-09-03
CY1113578T1 (el)	2016-06-22
PL409525A1 (pl)	2014-11-10
FR14C0066I2 (fr)	2015-05-22
RU2005114017A (ru)	2006-01-20
CN102532162B (zh)	2015-05-27
HK1085463A1 (en)	2006-08-25
ES2400179T3 (es)	2013-04-08
CA2497569A1 (fr)	2004-04-22
CN101172981A (zh)	2008-05-07
HUS1400046I1 (hu)	2017-04-28
TWI347946B (en)	2011-09-01
KR100723847B1 (ko)	2007-05-31
US7262212B2 (en)	2007-08-28
AR086485A2 (es)	2013-12-18
DK1555267T3 (da)	2013-02-11
CY2014041I2 (el)	2016-07-27
AR091771A2 (es)	2015-02-25
AU2003272979A1 (en)	2004-05-04
EP1555267A4 (fr)	2010-08-18
JP2004149527A (ja)	2004-05-27
BRPI0314344B8 (pt)	2021-05-25
ZA200501033B (en)	2006-06-28
FR14C0066I1 (fr)	2014-10-17
CN100366624C (zh)	2008-02-06
EP2570418A2 (fr)	2013-03-20
PL217919B1 (pl)	2014-09-30
EP2570418A3 (fr)	2013-07-03
PL376157A1 (en)	2005-12-27
CY2014041I1 (el)	2016-07-27
BE2014C053I2 (fr)	2022-08-30
PT1555267E (pt)	2013-01-29
EP1555267B1 (fr)	2013-01-16
MXPA05003674A (es)	2005-06-08
CN1705670A (zh)	2005-12-07
TW200420568A (en)	2004-10-16
EP1555267A1 (fr)	2005-07-20
CN102532162A (zh)	2012-07-04
AR041198A1 (es)	2005-05-04
HK1171018A1 (en)	2013-03-15
WO2004033463A1 (fr)	2004-04-22
RU2326121C3 (ru)	2021-09-17
CA2497569C (fr)	2011-05-24
SI1555267T1 (sl)	2013-05-31
AU2003272979B2 (en)	2009-07-23
AR089950A2 (es)	2014-10-01
JP4186065B2 (ja)	2008-11-26
RU2326121C2 (ru)	2008-06-10
MY139244A (en)	2009-09-30
KR20050061473A (ko)	2005-06-22
BR0314344A (pt)	2005-07-12
PL404913A1 (pl)	2013-09-30
BRPI0314344B1 (pt)	2019-11-26
US20060094767A1 (en)	2006-05-04

Publication	Publication Date	Title
LU92517I2 (fr)	2014-10-13	Delamanide et ses dérivés pharmaceutiquement acceptables
LU92513I2 (fr)	2015-11-02	Sofosbuvir et ses dérivés pharmaceutiquement acceptables (solvaldi)
LU92419I2 (fr)	2014-06-02	Riociguat et ses dérivés pharmaceutiquement acceptables (ADEMPAS®)
LU93093I2 (fr)	2016-08-01	Nécitumumab et ses dérivés pharmaceutiquement acceptables (portrazza)
LU92336I2 (fr)	2014-02-17	Trastuzumab emtansine et ses dérivés pharmaceutiquement acceptables (KADCYLA)
LU92381I2 (fr)	2014-04-28	Macitentan et ses dérivés pharmaceutiquement acceptables (OPSUMIT)
LU92871I2 (fr)	2016-01-13	Fumarate de diméthyle et ses dérivés pharmaceutiquement acceptables (tecfidera)
LU92024I2 (fr)	2012-08-20	Pasireotide et ses dérivés pharmaceutiquement acceptables (SIGNIFOR)
LUC00127I2 (fr)	2020-10-06	Dacomitinib et ses derives pharmaceutiquement accepatbles ( vizimpro )
LU91624I2 (fr)	2010-01-25	Canakinumab et ses dérivés pharmaceutiquement acceptables (ILARIS®)
IS2599B (is)	2010-04-15	3-fenýlsúlfónýl-8-píperasín-1-ýl-kínólín og lyfjafræðilega viðurkenndar afleiður þess
LU92326I2 (fr)	2014-02-05	Canakinumab et ses dérivés pharmaceutiquement acceptables (ILARIS)
LU92182I2 (fr)	2013-06-17	Dapagliflozine et ses sels pharmaceutiquement acceptables
LU91883I2 (fr)	2013-04-12	Pradofloxacin et ses dérivés pharmaceutiquement acceptables (VERAFLOX®)
LU91757I2 (fr)	2011-01-24	Denosumab et ses dérivés pharmaceutiquement acceptables (PROLIA®)
LU92745I2 (fr)	2015-08-17	Nétupitant/Palonosétron et leurs dérivés pharmaceutiquement acceptables (AKYNZEOr)
LU92634I2 (fr)	2015-11-02	Flutémétamol (18f) et ses dérivés pharmaceutiquement acceptables (vizamyl)
LU91269I2 (fr)	2006-09-26	Rotigotine et ses dérivés pharmaceutiquement acceptables (neupro)
IS7948A (is)	2005-07-20	Fosfónóoxýkínasólínafleiður og lyfjafræileg notkun þeirra
IS7872A (is)	2005-05-30	Pýrrólópýrimidín afleiður
ATE478870T1 (de)	2010-09-15	Spiroindolinpiperidinderivate
DK1556385T3 (da)	2010-06-14	Heterocyclocarboxamid-derivater
DE60330372D1 (de)	2010-01-14	Indol-3-schwefelderivate
ATE467631T1 (de)	2010-05-15	Chinuclidinamidderivate
IS7720A (is)	2005-03-01	Píperidín-N-oxíð-afleiður